-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Allogene Therapeutics, Raises Price Target to $8

Benzinga·03/13/2026 16:24:06
Listen to the news
Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and raises the price target from $7 to $8.